BioPharma Dive1h
Intellia data spark debate about CRISPR drug’s potential
Newly published data show the therapy reduced the rate of swelling attacks in people with hereditary angioedema, but didn't ...
CRISPR-Cas9 gene editing trial results support further development as treatment for hereditary angioedema
A single treatment with a CRISPR-Cas9 based gene editing therapy is enough to replace the daily medication of patients with ...
technologynetworks17h
CRISPR-Cas9 Therapy Shows Promise As Single-Dose Treatment for Hereditary Angioedema
A single treatment with, a CRISPR-Cas9-based gene editing therapy, is enough to replace the daily medication of patients with ...
Intellia slips after mid-stage data for CRISPR-based hereditary angioedema therapy
Intellia Therapeutics (NASDAQ:NTLA) fell ~9% in the pre-market on Thursday after the biotech announced data from an ongoing ...
FierceBiotech4h
Intellia links in vivo CRISPR therapy to 81% drop in HAE attacks in phase 2
Intellia Therapeutics has taken another step toward its goal of winning the first approval for an in vivo CRISPR therapy, ...
healthday1h
ACAAI: Gene-Editing Therapy Reduces Angioedema Attacks in Hereditary Angioedema
For adults with hereditary angioedema, the in vivo gene-editing therapy NTLA-2002, which is based on clustered regul ...
Poseida Therapeutics to present data on P-KLKB1-101 in hereditary angioedema
Poseida Therapeutics (PSTX) announced the upcoming presentation of new preclinical data supporting the potential of P-KLKB1-101, a ...
Armed robbery in Revesby5h
CRISPR-Cas9 Phase 2 Boosts Hereditary Angioedema Hope
A single treatment with, a CRISPR-Cas9 based gene editing therapy, is enough to replace the daily medication of patients with ...
Poseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary Angioedema
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing ...
Biocryst Presents New Real-World Evidence Showing High Adherence And Persistence Rates With ORLADEYO® (Berotralstat)
Additional real-world studies show sustained HAE attack rate reduction after initiating ORLADEYO, regardless of C1-INH status, and patient preference ...
Business Wire6d
KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that five abstracts have been accepted for e-Poster ...
EurekAlert!5h
Phase Two results with CRISPR-Cas9 gene editing support further development as treatment for hereditary angioedema (HAE)
A single treatment with, a CRISPR-Cas9 based gene editing therapy, is enough to replace the daily medication of patients with hereditary angioedema (HAE), a condition characterized by severe, painful ...